Currently, one clinical trial is evaluating the efficacy of this approach (NCT00004918); ii. K562/GM-CSF (GVAX), a cell-based vaccine derived from K562 cells genetically modified to produce granulocyte-macrophage colony-stimulating factor (GM-CSF) and a number of LAAs which recruit dendritic cells and activate T cell-mediated CML-specific immune responses. Here, CSF2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.